Xeris Pharmaceuticals Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- Xeris Pharmaceuticals's estimated revenue is currently $2.5M per year.
- Xeris Pharmaceuticals received $10.0M in venture funding in March 2018.
- Xeris Pharmaceuticals's estimated revenue per employee is $15503
- Xeris Pharmaceuticals's total funding is $237.6M.
- Xeris Pharmaceuticals has 159 Employees.
- Xeris Pharmaceuticals grew their employee count by 85% last year.
- Xeris Pharmaceuticals currently has 13 job openings.
|John Shannon||Chief Operating Officer|
|Allison Wey||Senior Vice President, Investor Relations & Corporate Communications|
|Ed Drower||Director Quality|
|Mike Davis||Director, Quality Control|
|Aziz Alam||Director of Global Regulatory Affairs|
|John T. Mathis||Regional Medical Affairs Director|
|Kristin Marvin||Deputy General Counsel and Vice President of Legal Affairs|
|Kendal Korte||Director of HR and Office Services|
|Kenneth Johnson||Senior Vice President - Clinical Development, Medical Affairs and QA|
|Phil Estepa||Director of Device Development (Combination Products)|
What Is Xeris Pharmaceuticals?
Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare systemkeywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Solar Power
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Care One Pharma...||$7.8M||42||24%|
|Firma Clinical ...||$15.7M||83||0%|
Xeris Pharmaceuticals News
After a three-month PDUFA extension, Xeris Pharmaceuticals and XERS investors are preparing for Gvoke's new PDUFA date on September ...
So shareholders might well want to know whether insiders have been buying or selling shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS).
Xeris Pharma's Gvoke is a stable and ready to use glucagon self-injector therapy. It has shown non-inferiority to Lilly and Novo Nordisk ...
Xeris Pharmaceuticals Funding
|2011-12-13||$1.5M||A||Central Texas Angel Network||Article|
|2018-03-09||$45.0M||Undisclosed||Silicon Valley Bank||Article|
Xeris Pharmaceuticals Executive Hires